Science, Synthetic Biology, Best of 2016, Fashion, Big Data.
treatment involves isolating the patient’s T-cells, deleting a gene called PD-1 that normally stops the immune cells from attacking cancer, and re-injecting the edited cells into the patient. The first U.S. trial, scheduled to begin in early 2017 at the University of Pennsylvania, will focus on the